TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05838014

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sleep deprivation
Description: Participants will undertake a period of 24 hours of total sleep deprivation prior to completing exercise

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Normal sleep
Description: Participants will undertake \~8 hours of normal sleep prior to completing exercise
Study: NCT05682300

Intervention type: PROCEDURE
Intervention: peripheral nerve block
Description: After signing the informed consent by the patient, specific for this observational study, the peripheral regional anesthesia technique will be performed following the usual practice of the anesthesiologist responsible for the surgery. Under standard monitoring and taking into account the necessary aseptic measures, either peripheral nerve blocks (for surgeries involving extremities) or fascial blocks (for surgeries involving the chest wall, abdomen, or spine) will be performed.
Study: NCT04597424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: doxycycline
Description: 2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.~If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Experimental: doxycycline
Description: 2 tablets of doxycycline 100 mg (monohydrate form) will be taken orally after each risk sexual intercourse, ideally within 24 hours after sex and no more than 72 hours. PEP should not be taken more than 3 times over a 7 days' period.~If a participant has risk sexual intercourse for several consecutive days, PEP should be taken at least 48 hours apart and no more than 3 times 2 tablets over 7 days. A maximum of 3 intakes of 2 tablets will be allowed over a period of 7 days.
Study: NCT05793034

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Biological biomarker assessment
Description: IHC, PCR, NGS, methylome
Study: NCT04597424

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero® vaccine
Description: 1st injection of Bexsero® vaccine at inclusion visit, 2nd injection at week 8.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Bexsero® vaccine
Description: 1st injection of Bexsero® vaccine at inclusion visit, 2nd injection at week 8.
Study: NCT05954273

Intervention type: PROCEDURE
Intervention: Osseodensification crestal sinsus graft
Description: Osseodensification Mediated Maxillary Sinus Crestal Grafting

Intervention type: PROCEDURE
Intervention: Osseodensification crestal sinsus graft
Description: Osseodensification Mediated Maxillary Sinus Crestal Grafting

Intervention type: PROCEDURE
Intervention: Osseodensification crestal sinsus graft
Description: Osseodensification Mediated Maxillary Sinus Crestal Grafting

Intervention type: PROCEDURE
Intervention: Osseodensification crestal sinsus graft
Description: Osseodensification Mediated Maxillary Sinus Crestal Grafting
Study: NCT04404075

Intervention type: OTHER
Intervention: SkinTracker Mobile App
Description: a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting
Study: NCT05594966

Intervention type: DIAGNOSTIC_TEST
Intervention: multimodal MRI
Description: patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI

Intervention type: DIAGNOSTIC_TEST
Intervention: multimodal MRI
Description: patients are diagnosed with cerebral small vessel disease preoperatively using multimodal MRI
Study: NCT05511909

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Buspirone
Description: Buspirone administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lofexidine
Description: Lofexidine administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants administration begins 2 days prior to opioid taper (study day -2) and continues until the second day of the post-taper observation phase (study day 7).
Study: NCT04909164

Intervention type: DRUG
Intervention: Immunnotherapy group
Description: Eligible patients are those who receive reimbursed immunotherapy or cytotoxic chemotherapy after failure of platinum-based chemotherapy per current health insurance reimbursement criteria.

Intervention type: DRUG
Intervention: Immunnotherapy group
Description: Eligible patients are those who receive reimbursed immunotherapy or cytotoxic chemotherapy after failure of platinum-based chemotherapy per current health insurance reimbursement criteria.

Intervention type: DRUG
Intervention: Immunnotherapy group
Description: Eligible patients are those who receive reimbursed immunotherapy or cytotoxic chemotherapy after failure of platinum-based chemotherapy per current health insurance reimbursement criteria.

Intervention type: DRUG
Intervention: Immunnotherapy group
Description: Eligible patients are those who receive reimbursed immunotherapy or cytotoxic chemotherapy after failure of platinum-based chemotherapy per current health insurance reimbursement criteria.
Study: NCT04404075

Intervention type: OTHER
Intervention: SkinTracker Mobile App
Description: a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting

Intervention type: OTHER
Intervention: SkinTracker Mobile App
Description: a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting

Intervention type: OTHER
Intervention: SkinTracker Mobile App
Description: a research-oriented eczema app to longitudinally track atopic dermatitis severity, symptoms, quality of life, physical activity, medication usage, and adverse events in a real-world setting
Study: NCT06419816

Intervention type: OTHER
Intervention: Physician-managed WellCheck use
Description: Physician-managed WellCheck use

Intervention type: OTHER
Intervention: self-managed WellCheck use
Description: self-managed WellCheck use
Study: NCT05741047

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: a2Milk skim milk powder
Description: a2Milk skim milk powder (1L) containing A2 β-casein only

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Yili skim milk powder
Description: Yili skim milk powder (1L) containing A1 and A2 β-caseins
Study: NCT05766033

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Enamel conditioning with a novel etchant paste
Description: The maxillary and mandibular incisors, canines, and premolars for each patient will be conditioned using the Novel etchent paste on one side (experimental), while the other side (control) conditioned with a phosphoric acid gel 37% . Both systems use identical brackets and adhesive system (differ only with regard to the etching system).

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Enamel conditioning with a novel etchant paste
Description: The maxillary and mandibular incisors, canines, and premolars for each patient will be conditioned using the Novel etchent paste on one side (experimental), while the other side (control) conditioned with a phosphoric acid gel 37% . Both systems use identical brackets and adhesive system (differ only with regard to the etching system).
Study: NCT06384716

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: rehabilitation programme based on motor control of core muscles
Description: The exercises performed during the intervention aim to improve the functionality of MS patients and to assess how this can improve pelvic floor health, quality of life, sexual health and urinary incontinence. A specific exercise programme has been designed and will be carried out by physiotherapists specialised in neurological physiotherapy for this purpose. The ultimate aim of the research is to be able to benefit other MS patients from our findings and to propose specific interventions in these areas. However, it is possible that no direct benefit will be obtained after the intervention. At the end of the research you will be informed, if you wish, about the main results and general conclusions of the study. The study does not pose any risk to your health as it is a non-invasive study and no harmful or deleterious action is incurred for the additional collection of the necessary records.
Study: NCT05954624

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Digoxin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZSP1273
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Probenecid
Description: oral
Study: NCT03202147

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cromolyn
Description: Active capsules for inhalation.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Non-active capsules for inhalation.
Study: NCT06482021

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shock wave
Description: Acetylcholine iontophoresis• The Iontophoresis comprises of electric impulses from a low voltage galvanic current stimulation unit to drive ions (Ach) (1%) into soft tissue structures.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Low-intensity extracorporeal shock wave
Description: Acetylcholine iontophoresis• The Iontophoresis comprises of electric impulses from a low voltage galvanic current stimulation unit to drive ions (Ach) (1%) into soft tissue structures.
Study: NCT06212518

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GENPOP ad libitum fluid intake
Description: Unrestricted fluid intake.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: GENPOP fluid restriction
Description: In the 24 hours between the first and last face scan, reduce fluid intake by approximately 75% (equating to approximately 700 ml (women) and 800 ml (men)).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ATHLETE ad libitum fluid intake
Description: No restriction on fluid intake

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ATHLETE restricted fluid intake
Description: Not permitted to drink during training session.
Study: NCT06477471

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MetProrenes
Description: Take one slow-release capsule twice a day, after meal.
Study: NCT05990023

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional vestibule rehabilitation training
Description: * Standing, using a gaze tracking system on a force plate to track a continuously moving target, with alerts when body sway exceeds a certain threshold.~* Standing, wearing an inertial sensor on the head and performing left-right or up-down head movements while maintaining gaze on a target, with a screen providing feedback on head movement speed.~* Standing, controlling body weight distribution on the force plate to reach a target position, with a screen displaying the current center of gravity position.~* Walking, synchronizing head movements with a rhythm or performing up-down head nods, with auditory cues indicating the desired head movement frequency.~* During continuous head rotations, stepping in a regular sequence of forward, backward, left, and right movements.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dual-task vestibule rehabilitation training
Description: * Adding a dual task of digit countdown and recitation to clinical balance training exercises.~* Incorporating a numerical calculation task into interactive screens during clinical balance training, with the participant's responses input by the researchers.~* Introducing upper limb exercises, such as button pressing or arm swinging, during clinical balance training.~* During continuous head rotations, following visual prompts on the display to perform forward, backward, left, and right displacements.
Study: NCT05848765

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epcoritamab
Description: Bispecific antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lenalidomide
Description: Immunomodulatory agent

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Immunomodulatory agent

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: Monoclonal antibody

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustine
Description: Alkylating agent (chemotherapy drug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristine
Description: Antineoplastic, Vinca Alkaloid

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxorubicin
Description: Anthracycline

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide
Description: Alkylating agent (chemotherapy drug)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: Corticosteroid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigation agent 2
Description: The drug used in round 2 is yet to be confirmed, round 2 is estimated to open in Q4 2025 and the record will be updated when the drug has been confirmed

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Investigation agent 3
Description: The drug used in round 3 is yet to be confirmed, round 3 is estimated to open in Q3 2027 and the record will be updated when the drug has been confirmed
Study: NCT06060860

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive-Behavioral Therapy (CBT)
Description: The UP incorporates common principles among empirically supported CBT protocols, including restructuring maladaptive cognitions, changing maladaptive behaviors, preventing emotion avoidance, and incorporating exposure. It consists of five core treatment modules:~1. emotion awareness,~2. cognitive appraisal \& reappraisal,~3. emotion avoidance \& emotion-driven behaviors,~4. awareness and tolerance of emotion-related physical sensations, \&~5. interoceptive and situational emotion-focused exposures.~There are two introductory modules on enhancing motivation and understanding of emotional experiences. A final module is on maintenance and relapse prevention. Modules are delivered at a flexible pace and some patients may spend multiple sessions on the same module. The total number of sessions varies from patient to patient, generally ranging from 12-18 sessions (50-60 minutes) delivered weekly. All sessions are 1:1 via telehealth.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Cognitive Therapy (MBCT)
Description: The study MBCT protocol is a 9-week program (90-120 minute sessions) with home-based practice between sessions. MBCT sessions incorporate formal mindfulness meditation practices such as sitting meditation, mindful movement, and body scan (with a focus on mindful and non-judgmental attention to sensations, thoughts, and feelings), as well as informal practices and homework to integrate mindful awareness into everyday life, such as mindful eating, mindful walking, and mindful breathing. All sessions are 1:1 via telehealth.
Study: NCT06466993

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Intervention of standardized relaxing breathing
Description: Relaxing breathing standardized to 6 respiratory cycles per minute that occur during rotation time before next station of OSCE start

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention of standardized relaxing breathing
Description: Relaxing breathing standardized to 6 respiratory cycles per minute that occur during rotation time before next station of OSCE start
Study: NCT04722796

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: TAVR with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)
Description: Transcatheter aortic valve replacement (TAVR) with Venus A plus using supra-annular sizing and THV implantation technique (Hangzhou solution)

Intervention type: DEVICE
Group type: OTHER
Intervention: TAVR with Venus A plus using annular sizing and THV implantation technique
Description: Transcatheter aortic valve replacement (TAVR) with Venus A plus using annular sizing and THV implantation technique (Traditional sizing strategy)
Study: NCT05367141

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CDSS (MedicBK)
Description: Clinical decision support system (MedicBK) is a computer-based program that analyzes published evidence and provides prompts and reminders to assist health care providers in implementing clinical guidelines and science-based medicine at the point of care.
Study: NCT06414330

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ringer acetate based Del Nido cardioplegia
Description: All patients will receive hypothermia 29 - 32 ℃ and cardioplegia will be injected between the aortic valve and aortic cross clamp in a pressure not less than 50 mmHg above systolic pressure. After removal of aortic cross clamping, the heart will be monitored for ventricular arrhythmias, early recovery, and postoperative 24 hours serum troponin and new changes in echocardiography.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: HTK
Description: Giving HTK instead of Del Nido
Study: NCT05065567

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Droperidol
Description: Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 2.5mg droperidol IV

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Haloperidol
Description: Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to 5mg haloperidol IM

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ondansetron 8mg
Description: Patients with suspected cannabis hyperemesis syndrome and enrolled in the study will be randomized based on the week to ondansetron
Study: NCT05995041

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
Description: Infusion of CLL-1, CD33, CD38 and/or CD123-specific universal CAR- T cells
Study: NCT04810611

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti-TIM3 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti-TIM3 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MBG453
Description: Anti-TIM3 monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Anti-TGF-β monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NIS793
Description: Anti-TGF-β monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: Anti-IL-1β monoclonal antibody

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: canakinumab
Description: Anti-IL-1β monoclonal antibody
Study: NCT06454409

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Given IV
Study: NCT06312241

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Metacognitive Training-Silver BeWell
Description: Metacognitive Training- Silver BeWell is a cognitive behavioral based group intervention, which focuses on helping participants gain (metacognitive) distance from thought and behavioral patterns as well as behaviors and ER-strategies that are implicated in the onset of depression and reduced overall mental well-being. In 10 modules, MCT-Silver addresses issues specific to later life such as coping with physical changes and loss, as well as adapting to new (social) roles. The program also includes modules on identifying and re-defining values in later life, acceptance of negative feelings and resilience. In the training participants are made aware of information processing biases that have been shown to contribute to the onset of depression through engaging exercises using examples from daily life. Groups are comprised of up to 10 participants. Each session is 90 minutes.
Study: NCT04860622

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum thyroid function tests
Description: At the first hospital visit, the blood tests will be made for TSH, FT4, FT3, and beta HCG concentration measurement
Study: NCT06135363

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC1011
Description: SC1011 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SC1011
Description: SC1011 tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: SC1011-matching placebo tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo tablet
Description: SC1011-matching placebo tablet
Study: NCT04754230

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid 1,000 Mg/10 mL (100 Mg/mL) INTRAVEN VIAL (ML)
Description: Medication administered 15 minutes prior to end of surgery.
Study: NCT05371041

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Percept Neurostimulator
Description: This is a deep brain stimulator that can also record brain signals and deliver stimulation through a control algorithm based on brain activity.
Study: NCT05077098

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ADXS-504
Description: ADXS-504 will be administered as monotherapy at 2 dose levels. Subjects who are assigned to receive Dose Level 1 (DL1) will be administered ADXS-504 at a dose of 1×107 CFU q4 weeks (±3 days) from Week 1 to Week 21. Subjects who are assigned to receive Dose Level 2 (DL2) will be administered ADXS-504 at a dose of 1×108 CFU q4 weeks (±3 days; Week 1 to Week 21). All 3-6 subjects must be enrolled in DL1, and DL1 must be confirmed safe, before enrollment for DL2 may begin. For both dose levels, these doses are followed by maintenance dosing at each respective dose level given every 12 (q12) weeks (±3 days) for 4 doses for overall total of 10 doses of the study treatment. If DL1 is deemed to exceed the MTD, dose reduction of ADXS-504 to DL-1 (1×106 CFU) may proceed. Dose level -1, intermediate dose levels or expansion of a cohort may also be further evaluated if recommended by the Investigator and Advaxis in future amendments.
Study: NCT04892251

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: MORE+KAP
Description: Mindfulness-Oriented Recovery Enhancement plus two sessions where 0.5 to 1.5 mg/kg of ketamine are administered intramuscularly

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: MORE
Description: Mindfulness-Oriented Recovery Enhancement